Free Domestic Shipping On Orders Over $100

Your Cart is Empty


Antaeus Labs


NEW LipoMorph by Antaeus Labs: Advanced Thermogenesis Activation Complex! Antaeus Labs is proud to present Lipo-Morph, a weight-management supplement at the cutting edge of scientific understanding of human physiology. Lipo-Morph is the first “fat burner” supplement to specifically target all known modifiable mechanisms of white fat browning, and both brown and beige fat activation. White Fat Ordinary white fat stores energy in the form of fat droplets, one droplet per adipocyte, which can be broken down by lipolysis into free fatty acids which are circulated into the blood stream and transported to the fuel-requiring tissue where they undergo beta-oxidation to acetyl-CoA which can be used to generate energy through the Krebs cycle. The energy stored in white fat, when liberated, is primarily burned to produce ATP to power cells. Unfortunately, modern Western diet and lifestyle habits (consisting of excessive caloric intake typically coupled with insufficient physical activity) can cause an excessive accumulation of both subcutaneous and visceral white adipose tissue (WAT) that can have numerous adverse effects on health and health markers. Brown Fat Brown fat is a thermogenic tissue that turns energy (stored as triglycerides) into heat. It’s found in abundance in hibernating mammals. When the temperature drops, animals like bears “go to sleep for the winter”. They’re able to survive by burning reserves of energy which have been stored as white and brown fat. The heat produced by the brown fat, which is activated by the cold, maintains the essential core body temperature of the animal through the winter months. It’s also found in high quantities in babies, but is present in much smaller amounts in adult humans. Unlike adults, babies are unable to regulate their own temperature by, say, putting on a coat or moving to a warmer room, so their ability to regulate their own temperature is more vital to their survival. Accordingly, they have greater amounts of brown fat which is widely distributed viscerally and subcutaneously, decreasing as age increases until as adults brown fat is largely limited to small deposits in the lower neck and supraclavicular region. These deposits are suspected to be useful in cold weather for warming blood as it flows to the brain. Brown fat appears brown in color because of the high density of mitochondria and excellent blood supply. Certain natural conditions, like endurance exercise and cold temperatures, can encourage the human body to produce and/or activate brown fat. Thermogenesis in brown fat is mediated by thermogenin, also known as uncoupling protein 1 (UCP1). UCP1 is specific to the mitochondria of brown fat, and functions as a proton transporter, uncoupling oxidative phosphorylation from ATP synthesis and allowing the resulting energy to dissipate in the form of heat. The thermogenic effect of UCP1 is known as “non-shivering thermogenesis”. Beige Fat In addition to classical brown fat, which originates from the same progenitor cells as muscle tissue, brown-like fat expressing the same thermogenic genes as brown fat can be made from regular mature white fat cells and their precursors. This brown-from-white fat is variously termed “brite” or “beige” fat, and the process of its creation known as “browning” of white fat. Whereas excessive white adipose tissue (WAT) impairs health, the recruitment and activation of brown and beige adipose tissue is currently being investigated as being potentially beneficial in the fight against obesity and metabolic disorders. Regulators of Brown & Beige Fat Natural regulators of brown and beige fat include external conditions like cold temperatures, and exercise, as well as internal mechanisms like thyroid hormones, beta-adrenergic hormones, retinoids, PPARγ and PPARα agonists, and the liver X receptor. Exercise & Peroxisome Proliferator-Activated Receptors Exercise has a number of positive health benefits, particularly regular, sustained aerobic exercise. One of the mediators of the positive metabolic effects of endurance exercise is peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α). PGC-1α is a transcriptional coactivator that binds to and activates transcription factors that regulate the genes involved in energy metabolism. It has a number of functions in the body, including influencing muscle fiber type determination, controlling lactate metabolism, and increasing amino acid breakdown in response to exercise stimulus. One of the products of amino acid breakdown in muscle tissue is β-aminoisobutyric acid (BAIBA), arising from the degradation of thymine and valine. BAIBA is believed to act as a messenger signalling molecule, released into the blood stream by exercise, that helps the body respond to demands for more energy by increasing β-oxidation of fatty acids. It’s also recently been discovered that BAIBA can induce white adipose tissue (WAT) to express brown fat-specific genes – including the all-important thermogenic UCP1. β-aminoisobutyric Acid What is it? BAIBA is a naturally occurring amino acid, a product of the metabolism of thymine and valine. [1][2] Levels of BAIBA are increased significantly by endurance exercise, a result of PGC1α-mediated amino acid breakdown. [3] Target(s): BAIBA exerts its effects on hepatocytes (liver cells) and white adipocytes (fat cells) through PPARalpha (PPARα). [4] PPARα regulates the use of fat as a source of energy. [5] Research Summary: Activation of PPARα in the liver and adipose tissue promotes lipolysis and beta oxidation of fatty acids. [5] PPARα activation stimulates white fat cell precursors to differentiate into beige/brite adipocytes. [4] PPARα agonism also induces mature white adipocytes to develop a beige/brite phenotype. [4] PPARα agonists increase UCP-1 mRNA levels in brown fat. [6] PPARα agonism in the small intestine is thought to be involved in the regulation of satiety (lack of hunger). [7][8] Coadministered PPARα and β3 adrenoceptor agonists may have a synergistic effect on the browning of white fat and UCP1-mediated thermogenesis. [9] BAIBA induces human stem cells, under conditions that would normally result in white adipocyte differentiation, instead to express brown-fat specific genes like UCP-1. [4] BAIBA induced increased expression of brown/beige fat-specific genes in an in vivo experiment on mice. [4] BAIBA levels are increased after endurance exercise, and may be responsible for some of the metabolic benefits of exercise. [4] BAIBA increases hepatic fatty acid oxidation and decreases fat mass in mice [10] Some of the fat-loss effects of thymine-based prescription drugs in humans may be due to an increase in utilization of free fatty acids resulting from the production of BAIBA as a metabolite. [10] Rats and mice treated with BAIBA and other PPARα agonists lose more body fat and gain less body weight than control animals. [11][7][9][10][4] Cold Temperatures & Beta-Adrenergic Hormones The thermogenic effects of brown fat can be activated in several ways; in hibernating animals and babies the trigger is cold temperatures. Cold temperatures trigger a release of norepinephrine into the blood stream, an adrenergic hormone which has several important roles, one of which is to activate brown fat via the beta-3 adrenergic receptor (β3 adrenoreceptor). Unlike other beta adrenergic receptors, which are widely distributed about the body, being found in cardiac tissue, skeletal and smooth muscle, and adipose tissue, distribution of β3 receptors are restricted to a few tissues – including brown fat, where activation increases energy expenditure. Brown fat also expresses heat-sensing receptors of its own. The receptor that detects cold temperatures is the cold and menthol receptor 1 (CMR1), more formally known as the transient receptor potential cation channel subfamily M member 8 (TRPM8).The transient receptor potential channels (TRPs) help the peripheral nervous system detect important variations in temperature; TRPV1 detects and regulates heat, but can also be activated by things like capsaicin (which is why chili peppers taste hot), and TRPM8 detects cold but can also be activated by compounds like menthol (which is why peppermint tastes cold). Thermogenesis in brown fat can be triggered by TRPM8 activation or norepinephrine release (β3 adrenoreceptor agonism). Human white adipose tissue also expresses the cold-sensing receptor TRPM8, which, when activated, transdifferentiates to a brown-like phenotype expressing UCP-1. Octopamine What Is It? Octopamine is a naturally-occurring endogenous amine found in plants such as bitter orange as well as vertebrates and invertebrates. [12][13] Target(s): Octopamine is a selective agonist of the mammalian beta-3 adrenergic receptor (β3adrenoreceptor). [14][15] Beta-3-adrenoceptor agonism is one of the primary regulators of brown fat activationand beige fat recruitment. [16] Research Summary: Beta-3-adrenoceptor activation is believed to be required for the transdifferentiationof mature white fat cells into brite/beige adipocytes. [16] Octopamine stimulates lipolysis in white fat cells and increased oxidation in brown fatcells in several mammal species. [15] Octopamine stimulates fatty acid oxidation in the liver, which may help prevent free fatty acids being reabsorbed into adipocytes. [17] Menthol What is it? (−)-Menthol is a naturally-occurring compound found in wild mint and peppermint. Target(s): Menthol is an agonist of the TRPM8 receptor, also known as the cold and menthol receptor. TRPM8 activation triggers thermogenesis in brown fat by mimicking long-term cold exposure. [18] Menthol is also an agonist of transient receptor potential A1 (TRPA1) in humans, [19] another thermosensitive (cold-sensing) receptor that has been linked to brown fat activation in animal models. [20] Research Summary: Dietary menthol induced non-shivering thermogenesis in mice without influencing metabolic markers such as heart rate or thyroid hormone levels. [18] Human white adipose tissue also expresses the cold-sensing receptor TRPM8, which, when activated by menthol, transdifferentiates to a brown-like phenotype expressing UCP-1. [21] A human clinical trial is currently recruiting participants to determine the metabolic effects of menthol. [22] Retinoids and LXR Ilex Kudingcha Extract What Is It? Ilex Kudingcha (Ilex kaushue) is a species of the holly genus of plants. In China the leaves are dried and brewed into a tea called Kuding. The bitter-tasting Kuding tea has been used for millennia as a traditional chinese medicine (TCM) for a variety of ailments. Target(s): Kuding has the ability to suppress the activity of the Liver X Receptor beta (LXRβ) through antagonist activity. [23] LXRβ antagonism results in decreased transcriptional activity of the enzyme sterol regulatory element-binding protein-1c (SREBP-1c), which is required for lipogenesis. [24] Research Summary: LXRβ is believed to be a regulator (repressor) of UCP-1 activity. [25] LXRβ antagonism may cause UCP1 transcription to be activated through an increase in PGC1α expression. [25] Vitamin A What is it? One of the forms of vitamin A is retinol. This animal-derived retinoid is essential for healthy skin, bone, and teeth. The main active metabolite of vitamin A is retinoic acid. Target(s): Retinoic acid binds to and activates the retinoic acid receptor (RAR). The vitamin A metabolite 9-cis-retinoic acid is an endogenous ligand of the retinoid X receptor (RXR) Research summary: Retinoic acid activates transcription of uncoupling protein-1 (UCP-1) both in vitro and in vivo. [26][27] Retinoic acid is necessary for induction of human UCP1 by beta-adrenergic agonists. [28] Retinal (retinaldehyde), another retinol metabolite, induces browning of white fat through activation of the retinoic acid receptor (RAR). [29] Other Regulators of Beige & Brown Fat Fucoxanthin What Is It? Fucoxanthin is a naturally-occurring xanthophyll found in brown algae and edible seaweed. Target(s): Some of fucoxanthin’s putative anti-obesity effects may be via downregulation of PPAR-γ.[30] Research summary: Fucoxanthin increases the metabolic rate, induces the browning of white fat, and upregulates UCP1 (thermogenin) expression in mice. [31] Mice fed a high fat diet and supplemental fucoxanthin had increased expression of β3-adrenergic receptor mRNA in white fat tissue. [32] In in vitro experiments, fucoxanthin and its metabolites suppress adipogenesis via downregulation of PPAR-γ. [30] Fucoxanthin increases phosphorylation of AMP-activated protein kinase (AMPK) and acetyl-CoA carboxylase (ACC) and decreases the expression of SREBP1c in mouse adipose tissue, promoting β-oxidation of fatty acids and reducing lipogenesis [33] A human study on obese non-diabetic women given a commercial product containing fucoxanthin and pomegranate seed oil found that it increase the resting energy expenditure of the participants and promoted weight loss. [34] Stearoyl Vanillylamide What Is It? Stearoyl vanillylamide is a naturally-occurring capsaicin analogue found in red pepper species. Capsaicin is responsible for the hot/burning feeling caused by chili peppers. Unlike capsaicin, stearoyl vanillylamide is nonpungent, meaning it does not impart the “spicy” or irritative effects of capsaicin. Target(s): Stearoyl vanillylamide, capsaicin and similar compounds activate the transient receptor potential cation channel V1 (TRPV1). Research Summary: TRPV1 activation stimulates the release of catecholamines such as adrenaline and noradrenaline from the adrenal medulla. [35] Noradrenaline is a major regulator of brown fat activation, through β3 adrenoreceptor activation. Nonpungent capsaicin analogs have been demonstrated to activate brown adipose tissue and increase energy expenditure in a human clinical trial. [36] A systematic review of human clinical trials observed that regular consumption of capsaicinoids increased energy expenditure, and significantly reduced abdominal adipose tissue levels. [37] Chronic TRPV1 activation by dietary TRPV1 agonists can increase phosphorylated levels of protein kinase A (PKA) and endothelial NO synthase (eNOS), causing peripheral vasodilation and a decrease in blood pressure in hypertensive rats. [38] The oral administration of TRPV1 agonists prevents adipogenesis and obesity in mice fed a high-fat diet. [39] Stearoyl vanillylamide increased lipolysis and oxidation of free fatty acids in rats, resulting in increased capacity for exercise [40] Some non-pungent capsinoids have also been found to activate TRPA1, another receptor that may be involved in cold detection. [41] Lipo-Morph encapsulates the most cutting-edge scientific understanding of nutritional manipulation of metabolic regulation, and as such represents the most complete natural thermogenic formula on the market. References: [1] Nielsen, H.R., Sjølin, K.-E., Nyholm, K., Baliga, B.S., Wong, R., and Borek, E. (1974). β-Aminoisobutyric Acid, a New Probe for the Metabolism of DNA and RNA in Normal and Tumorous Tissue. Cancer Res 34, 1381–1384. [2] Hillcoat, B.L. (1961). The excretion of beta-aminoisobutyric acid following thymine and dihydrothymine administration to man. Aust J Exp Biol Med Sci 39, 423–427. [3] Hatazawa, Y., Tadaishi, M., Nagaike, Y., Morita, A., Ogawa, Y., Ezaki, O., Takai-Igarashi, T., Kitaura, Y., Shimomura, Y., Kamei, Y., et al. (2014). PGC-1α-Mediated Branched-Chain Amino Acid Metabolism in the Skeletal Muscle. PLoS ONE 9, e91006. [4] Roberts, L.D., Boström, P., O’Sullivan, J.F., Schinzel, R.T., Lewis, G.D., Dejam, A., Lee, Y.-K., Palma, M.J., Calhoun, S., Georgiadi, A., et al. (2014). β-Aminoisobutyric Acid Induces Browning of White Fat and Hepatic β-Oxidation and Is Inversely Correlated with Cardiometabolic Risk Factors. Cell Metabolism 19, 96–108. [5] Rakhshandehroo, M., Knoch, B., Müller, M., and Kersten, S. (2010). Peroxisome proliferator-activated receptor alpha target genes. PPAR Res 2010. [6] Barbera, M.J., Schluter, A., Pedraza, N., Iglesias, R., Villarroya, F., and Giralt, M. (2001). Peroxisome proliferator-activated receptor alpha activates transcription of the brown fat uncoupling protein-1 gene. A link between regulation of the thermogenic and lipid oxidation pathways in the brown fat cell. J. Biol. Chem. 276, 1486–1493. [7] Fu, J., Gaetani, S., Oveisi, F., Lo Verme, J., Serrano, A., Rodríguez de Fonseca, F., Rosengarth, A., Luecke, H., Di Giacomo, B., Tarzia, G., et al. (2003). Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-α. Nature 425, 90–93. [8] Lo Verme, J., Gaetani, S., Fu, J., Oveisi, F., Burton, K., and Piomelli, D. (2005). Regulation of food intake by oleoylethanolamide. Cell. Mol. Life Sci. 62, 708–716. [9] Suárez, J., Rivera, P., Arrabal, S., Crespillo, A., Serrano, A., Baixeras, E., Pavón, F.J., Cifuentes, M., Nogueiras, R., Ballesteros, J., et al. (2014). Oleoylethanolamide enhances β- adrenergic-mediated thermogenesis and white-to-brown adipocyte phenotype in epididymal white adipose tissue in rat. Dis Model Mech 7, 129–141. [10] Maisonneuve, C., Igoudjil, A., Begriche, K., Lettéron, P., Guimont, M.-C., Bastin, J., Laigneau, J.-P., Pessayre, D., and Fromenty, B. (2004). Effects of zidovudine, stavudine and beta-aminoisobutyric acid on lipid homeostasis in mice: possible role in human fat wasting. Antivir. Ther. (Lond.) 9, 801–810. [11] Guzmán, M., Lo Verme, J., Fu, J., Oveisi, F., Blázquez, C., and Piomelli, D. (2004). Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-activated receptor alpha (PPAR-alpha). J. Biol. Chem. 279, 27849–27854. [12] Tang, F., Tao, L., Luo, X., Ding, L., Guo, M., Nie, L., and Yao, S. (2006). Determination of octopamine, synephrine and tyramine in Citrus herbs by ionic liquid improved “green” chromatography. J Chromatogr A 1125, 182–188. [13] David, J.C., and Coulon, J.F. (1985). Octopamine in invertebrates and vertebrates. A review. Prog. Neurobiol. 24, 141–185. [14] Carpéné, C., Galitzky, J., Fontana, E., Atgié, C., Lafontan, M., and Berlan, M. (1999). Selective activation of beta3-adrenoceptors by octopamine: comparative studies in mammalian fat cells. Naunyn Schmiedebergs Arch. Pharmacol. 359, 310–321. [15] Fontana, E., Morin, N., Prévot, D., and Carpéné, C. (2000). Effects of octopamine on lipolysis, glucose transport and amine oxidation in mammalian fat cells. Comp. Biochem. Physiol. C Toxicol. Pharmacol. 125, 33–44. [16] Barbatelli, G., Murano, I., Madsen, L., Hao, Q., Jimenez, M., Kristiansen, K., Giacobino, J.P., De Matteis, R., and Cinti, S. (2010). The emergence of cold-induced brown adipocytes in mouse white fat depots is determined predominantly by white to brown adipocyte transdifferentiation. Am. J. Physiol. Endocrinol. Metab. 298, E1244–1253. [17] De Oliveira, A.L., de Paula, M.N., Comar, J.F., Vilela, V.R., Peralta, R.M., and Bracht, A. (2013). Adrenergic Metabolic and Hemodynamic Effects of Octopamine in the Liver. Int J Mol Sci 14, 21858–21872. [18] Ma, S., Yu, H., Zhao, Z., Luo, Z., Chen, J., Ni, Y., Jin, R., Ma, L., Wang, P., Zhu, Z., et al. (2012). Activation of the cold-sensing TRPM8 channel triggers UCP1-dependent thermogenesis and prevents obesity. J Mol Cell Biol mjs001. [19] Xiao, B., Dubin, A.E., Bursulaya, B., Viswanath, V., Jegla, T.J., and Patapoutian, A. (2008). Identification of the Transmembrane Domain Five as a Critical Molecular Determinant of Menthol Sensitivity in Mammalian TRPA1 Channels. J Neurosci 28, 9640–9651. [20] Tamura, Y., Iwasaki, Y., Narukawa, M., and Watanabe, T. (2012). Ingestion of cinnamaldehyde, a TRPA1 agonist, reduces visceral fats in mice fed a high-fat and highsucrose diet. J. Nutr. Sci. Vitaminol. 58, 9–13. [21] Rossato, M., Granzotto, M., Macchi, V., Porzionato, A., Petrelli, L., Calcagno, A., Vencato, J., De Stefani, D., Silvestrin, V., Rizzuto, R., et al. (2014). Human white adipocytes express the cold receptor TRPM8 which activation induces UCP1 expression, mitochondrial activation and heat production. Molecular and Cellular Endocrinology 383, 137–146. [22] Effects and Safety of Menthol on Blood Pressure and Metabolic Parameters in Prehypertensive and Mild Hypertensive Patients (ESMAB) Identifier: NCT01408446 [23] Fan, S., Zhang, Y., Hu, N., Sun, Q., Ding, X., Li, G., Zheng, B., Gu, M., Huang, F., Sun, Y.-Q., et al. (2012). Extract of Kuding tea prevents high-fat diet-induced metabolic disorders in C57BL/6 mice via liver X receptor (LXR) β antagonism. PLoS ONE 7, e51007. [24] Schultz, J.R., Tu, H., Luk, A., Repa, J.J., Medina, J.C., Li, L., Schwendner, S., Wang, S., Thoolen, M., Mangelsdorf, D.J., et al. (2000). Role of LXRs in control of lipogenesis. Genes Dev. 14, 2831–2838. [25] Korach-André, M., Archer, A., Barros, R.P., Parini, P., and Gustafsson, J.-Å. (2011). Both liver-X receptor (LXR) isoforms control energy expenditure by regulating Brown Adipose Tissue activity. PNAS 108, 403–408. [26] Puigserver, P., Vazquez, F., Bonet, M.L., Pico, C., and Palou, A. (1996). In vitro and in vivo induction of brown adipocyte uncoupling protein (thermogenin) by retinoic acid. Biochem J 317, 827–833. [27] Alvarez, R., de Andrés, J., Yubero, P., Viñas, O., Mampel, T., Iglesias, R., Giralt, M., and Villarroya, F. (1995). A novel regulatory pathway of brown fat thermogenesis. Retinoic acid is a transcriptional activator of the mitochondrial uncoupling protein gene. J. Biol. Chem. 270, 5666–5673. [28] Del Mar Gonzalez-Barroso, M., Pecqueur, C., Gelly, C., Sanchis, D., Alves-Guerra, M.C., Bouillaud, F., Ricquier, D., and Cassard-Doulcier, A.M. (2000). Transcriptional activation of the human ucp1 gene in a rodent cell line. Synergism of retinoids, isoproterenol, and thiazolidinedione is mediated by a multipartite response element. J. Biol. Chem. 275, 31722–31732. [29] Kiefer, F.W., Vernochet, C., O’Brien, P., Spoerl, S., Brown, J.D., Nallamshetty, S., Zeyda, M., Stulnig, T.M., Cohen, D.E., Kahn, C.R., et al. (2012). Retinaldehyde dehydrogenase 1 regulates a thermogenic program in white adipose tissue. Nat. Med. 18, 918–925. [30] Maeda, H., Hosokawa, M., Sashima, T., Takahashi, N., Kawada, T., and Miyashita, K. (2006). Fucoxanthin and its metabolite, fucoxanthinol, suppress adipocyte differentiation in 3T3-L1 cells. Int. J. Mol. Med. 18, 147–152. [31] Maeda, H., Hosokawa, M., Sashima, T., Funayama, K., and Miyashita, K. (2005). Fucoxanthin from edible seaweed, Undaria pinnatifida, shows antiobesity effect through UCP1 expression in white adipose tissues. Biochem. Biophys. Res. Commun. 332, 392–397. [32] Maeda, H., Hosokawa, M., Sashima, T., Murakami-Funayama, K., and Miyashita, K. (2009). Anti-obesity and anti-diabetic effects of fucoxanthin on diet-induced obesity conditions in a murine model. Mol Med Rep 2, 897–902. [33] Kang, S.-I., Shin, H.-S., Kim, H.-M., Yoon, S.-A., Kang, S.-W., Kim, J.-H., Ko, H.-C., and Kim, S.-J. (2012). Petalonia binghamiae extract and its constituent fucoxanthin ameliorate high-fat diet-induced obesity by activating AMP-activated protein kinase. J. Agric. Food Chem. 60, 3389–3395. [34] Abidov, M., Ramazanov, Z., Seifulla, R., and Grachev, S. (2010). The effects of XanthigenTM in the weight management of obese premenopausal women with non-alcoholic fatty liver disease and normal liver fat. Diabetes, Obesity and Metabolism 12, 72–81. [35] Watanabe, T., Kawada, T., Kato, T., Harada, T., and Iwai, K. (1994). Effects of capsaicin analogs on adrenal catecholamine secretion in rats. Life Sciences 54, 369–374. [36] Yoneshiro, T., Aita, S., Kawai, Y., Iwanaga, T., and Saito, M. (2012). Nonpungent capsaicin analogs (capsinoids) increase energy expenditure through the activation of brown adipose tissue in humans. Am. J. Clin. Nutr. 95, 845–850. [37] Whiting, S., Derbyshire, E., and Tiwari, B.K. (2012). Capsaicinoids and capsinoids. A potential role for weight management? A systematic review of the evidence. Appetite 59, 341–348. [38] Yang, D., Luo, Z., Ma, S., Wong, W.T., Ma, L., Zhong, J., He, H., Zhao, Z., Cao, T., Yan, Z., et al. (2010). Activation of TRPV1 by Dietary Capsaicin Improves Endothelium-Dependent Vasorelaxation and Prevents Hypertension. Cell Metab 12, 130–141. [39] Zhang, L.L., Yan Liu, D., Ma, L.Q., Luo, Z.D., Cao, T.B., Zhong, J., Yan, Z.C., Wang, L.J., Zhao, Z.G., Zhu, S.J., et al. (2007). Activation of transient receptor potential vanilloid type-1 channel prevents adipogenesis and obesity. Circ. Res. 100, 1063–1070. [40] Kim, K.-M., Kawada, T., Ishihara, K., Inoue, K., and Fushiki, T. (1998). Swimming Capacity of Mice Is Increased by Oral Administration of a Nonpungent Capsaicin Analog, Stearoyl Vanillylamide. J. Nutr. 128, 1978–1983. [41] Shintaku, K., Uchida, K., Suzuki, Y., Zhou, Y., Fushiki, T., Watanabe, T., Yazawa, S., and Tominaga, M. (2012). Activation of transient receptor potential A1 by a non-pungent capsaicin-like compound, capsiate. Br J Pharmacol 165, 1476–1486. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. LipoMorph Supplement Facts Serving Size: 1 Capsule Servings per Container: 60 Amount Per Serving % Daily Value Beta-aminoisobutyric Acid Monohydrate 250 mg ** Undaria Pinnatifida Extract (standarized to 50% Fucoxanthin) 166 mg ** Octopamine HCI 166 mg ** llex Kudungcha Extract 100 mg ** L-Menthol 75 mg ** Stearoyl Vanillylamide 16 mg ** Vitamin A (retinol) 3,500 IU 70% * Percent Daily Values are based on a 2000 calorie diet. ** Percent Daily Values not established. OTHER INGREDIENTS: Hypromellose, Microscrystalline cellulose, Silicon Dioxide. LipoMorph Directions: As a dietary supplement, take two capsules daily with food. We recommend taking one capsule with the first meal of the day and one capsule in the afternoon or evening with food. Users who weigh over 200 pounds may take three capsules per day if desired. Do not exceed four capsules in any 24 hour period. LipoMorph WARNING: This product is intended to be consumbed by healthy persons, who generally do not have health problems. Consult with a licensed physician before using this product, especially if you are taking any prescription, over the counter medication, dietary supplement product, or if you have any preexisting medical condition including but not limited to: high or low blood pressure, high or low cholesterol, cardiac arrhythmia, stroke, heart, liver, kidney or thyroid disease, seizure disorder, psychiatric disease, osteoporosis, diabetes, difficulty urinating due to prostate enlargement or if you are taking a MAO-B inhibitor or any other medication. Do not take this product if you have been diagnosed with prostate cancer, testicular cancer or breast cancer. Discontinue use 2 weeks prior to surgery. Discontinue use and immediately consult your heath care professional if you experience any adverse reaction to this product. Do not exceed recommended serving. Do not use if safety seal is broken or missing. KEEP OUT OF REACH OF CHILDREN.
News & Updates

Sign up to get the latest on sales, new releases and more …